Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05467553
Other study ID # 202108021MIPD
Secondary ID P1101-HDV
Status Not yet recruiting
Phase Phase 2
First received
Last updated
Start date February 24, 2023
Est. completion date August 31, 2025

Study information

Verified date July 2022
Source National Taiwan University Hospital
Contact Pei-Jer Chen
Phone 886-2-23123456
Email peijerchen@ntu.edu.tw
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is an open-label, randomized, multi-center study in patients with chronic HBV and HDV co-infection.


Description:

There will be 2 treatment groups in this study, 15 subjects per group as follows: Group 1: TAF 25 mg orally (PO) QD for 60 weeks with P1101 450 µg subcutaneously (SC) Q2W add-on at treatment week 12 for 48 weeks. Group 2: Ursodeoxycholic Acid (UDCA)* 15 mg/kg orally (PO) QD plus TAF 25 mg orally (PO) QD for 60 weeks, with P1101 450 µg subcutaneously (SC) Q2W add-on at treatment week 12 for 48 weeks. Both groups will have a post-treatment follow-up of 24 weeks. *: Dose of Ursodeoxycholic Acid (UDCA) will be determined by weight at Day 1 (TW0) in 2-4 divided doses.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 30
Est. completion date August 31, 2025
Est. primary completion date February 28, 2025
Accepts healthy volunteers No
Gender All
Age group 20 Years to 75 Years
Eligibility Inclusion Criteria: 1. Positive for HBsAg for at least 6 months, either HBeAg(+) or HBeAg(-), and positive for anti-HDV with detectable HDV RNA and ALT = ULN to = 10X ULN at screening. 2. Interferon treatment naïve. 3. Willing and able to provide written informed consent. 4. Age 20-75 years old; subjects who are over 70 years of age must be in generally good health. 5. Laboratory test results before study entry: WBC = 3,000/mm3; ANC = 1,500/mm3; Platelet = 90,000/mm3; Hemoglobin = 10g/dL; e-GFR = 60mL/min. 6. ECG without clinically significant abnormalities before study entry. 7. Be able to attend all scheduled visits and to comply with all study procedures. 8. Patients with anti-HCV(+) or anti-HIV(+) can be enrolled if: 1. anti-HCV(+) with undetectable HCV RNA = 3 months. 2. anti-HIV(+) with undetectable HIV viral load (either with or without Highly Active Anti- Retroviral Therapy, HAART). Exclusion Criteria: 1. Clinically significant illness or surgery that might interfere with study participation. 2. Clinically significant vital sign abnormalities, uncontrolled hypertension, or fever [body temperature >38 degrees Celsius]. 3. History of significant alcohol or drug abuse within 6 months prior to the screening visit (alcohol consumption of more than 14 units of alcohol per week [1 Unit = 150 mL of wine, 360 mL of beer, or 45 mL of 40% alcohol]) or refusal to abstain from alcohol or illicit drugs throughout the study. 4. Any history or presence of poorly controlled or clinically significant medical conditions that are not suitable to receive interferon-based treatment, at the discretion of the investigator: major psychiatric (including but not limited to those with severe depression, severe bi-polar disorder, schizophrenia, suicidal ideation or history of suicidal attempt), neurological, cardiovascular, pulmonary, hematologic, immunologic, autoimmune diseases, thyroid or other endocrine diseases, metabolic (e.g. diabetes mellitus with HbA1C > 8.0%) or other uncontrolled systemic disease, coagulation disorders or blood dyscrasias. 5. Pregnant subject; female subject who are breast feeding or lactating; female subject or the spouse of male subject, with child-bearing potential who is unwilling or unable to practice adequate contraception, defined as vasectomy in men, tubal ligation in women, or use of condoms and spermicides, or birth control pills, or intrauterine devices throughout the study. 6. History of severe allergic or hypersensitivity reactions, e.g. hypersensitivity to the active substance or to any of the excipients of ropeginterferon alfa 2b, ursodeoxycholic acid, tenofovir disoproxil fumarate and tenofovir alafenamide. 7. Therapy with any systemic anti-viral treatment, anti-neoplastic, or immunomodulatory treatment (including supraphysiologic doses of steroids and radiation) within 1 month (3 months for those with long elimination half-lives) prior to the first dose of study drug. 8. A depot injection or an implant of any drug within 3 months prior to administration of study medication, other than contraception or hyaluronic acid injections in joints for osteoarthritis. 9. Body organ transplant or taking immunosuppressant. 10. Use of an investigational drug within 4 weeks prior to the first dose of the study drug. 11. History of malignancy diagnosed or treated within 5 years prior to screening (except for localized treatment of squamous or non-invasive basal cell skin cancers; cervical carcinoma in situ); cancer survivors not on maintenance therapy within the past 5 years. 12. History of opportunistic infection (e.g., invasive candidiasis or pneumocystis pneumonia). 13. Serious localized infection (e.g., cellulitis, abscess) or systemic and life-threatening infection (e.g., septicemia) within 3 months prior to screening. 14. Clinically significant medical conditions known to interfere absorption, distribution, metabolism or excretion of the study drugs. 15. Decompensated liver disease, which includes but not limited to the following: total bilirubin = 2 mg/dL (except in Gilbert syndrome), direct bilirubin = 2X ULN, albumin level < 3.5 g/dL, INR = 1.5; clinical evidence of ascites, liver decompensation, hepatic encephalopathy, oesophageal varices or cirrhosis as identified by ultrasound or any other examination before study entry. 16. Significant steatohepatitis by ultrasound or other examination at the discretion of investigator. 17. Other form of significant chronic liver diseases, except those mentioned above. 18. Significant or major fundoscopic findings at screening including but not limited to retinal exudates, hemorrhage, detachment, neovascularization, papilloedema, optic atrophy, microaneurysms and macu-lar changes. 19. Patients with complete biliary obstruction, chololithiasis, severe pancreatic disease or peptic ulcer. 20. Patients treated by monotherapy of telbivudine/TDF/TAF/adefovir dipivoxil or any other combination therapy with telbivudine/TDF/TAF/adefovir dipivoxil within 1 month prior to screening. 21. Patient who vaccination with any live attenuated vaccine within 1 month prior to screening.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Ursodeoxycholic acid
Ursodeoxycholic Acid 15 mg/kg PO QD for 60 weeks
Ropeginterferon alfa-2b
P1101 450 µg SC Q2W add-on at treatment week 12 for 48 weeks
Tenofovir Alafenamide
TAF 25 mg PO QD for 60 weeks

Locations

Country Name City State
Taiwan National Taiwan University Hospital Taipei
Taiwan Taipei Medical University Hospital Taipei

Sponsors (2)

Lead Sponsor Collaborator
National Taiwan University Hospital PharmaEssentia

Country where clinical trial is conducted

Taiwan, 

Outcome

Type Measure Description Time frame Safety issue
Primary HDV RNA level Decline in HDV RNA = 2 log10 IU/mL at Week 60 Week 60
Primary ALT level ALT normalization (ALT < upper limit of normal) at Week 60 Week 60
Secondary Undetectable HDV RNA Undetectable HDV RNA (HDV RNA< low limit of quantifica-tion) at Week 60 and Week 84 Week 60 and Week 84
Secondary HBsAg level Reduction in HBsAg = 1 log10 IU/mL at Week 60 and Week 84 Week 60 and Week 84
Secondary Undetectable HBsAg HBsAg loss at Week 60 and Week 84 Week 60 and Week 84
Secondary HBsAg and anti-HBs level HBsAg seroconversion (HBsAg loss plus positive anti-HBs) at Week 60 and Week 84 Week 60 and Week 84
Secondary HDV RNA level Decline in HDV RNA = 2 log10 IU/mL at Week 84 Week 84
Secondary ALT level ALT normalization (ALT < upper limit of normal) at Week 84 Week 84
See also
  Status Clinical Trial Phase
Completed NCT02044055 - Mother-to-child Hepatitis D Transmission N/A
Completed NCT02375906 - The Hepatitis Delta International Network
Not yet recruiting NCT05394623 - Prevalence and Burden of Hepatitis D Virus Infection in China Through Preoperative Examination Test (Predict Study)
Recruiting NCT04863703 - Improvement of Portal Hypertension During Viral Suppression in Patients With Hepatitis Delta (IMPHROVE-D)
Recruiting NCT06397859 - Effectiveness and Clinical Outcomes of Long-term Bulevirtide Monotherapy in Patients With HDV-related Compensated Cirrhosis
Recruiting NCT00001971 - Evaluation of Patients With Liver Disease
Recruiting NCT06264583 - HDV-Europe: Prevalence and Outcome of HDV in HIV/HBV Coinfection
Recruiting NCT06122285 - Effectiveness and Safety of Bulevirtide (BLV) Therapy in Patients With Chronic Hepatitis Delta (CHD) in Italy (D-SHIELD)
Recruiting NCT05928000 - HEllenic Multicenter ReAl-life CLInical Study for Bulevirtide Therapy in Chronic Hepatitis D: HERACLIS-BLV
Terminated NCT04847440 - A Study of Safety and Efficacy of ATI-2173 in Combination With Tenofovir Disoproxil Fumarate in Subjects With Chronic Hepatitis B Virus Infection and in Subjects With Hepatitis D Virus Coinfection Phase 2
Recruiting NCT05936073 - DELTA DESCRIBE: the French Collaborative Project
Completed NCT00932971 - HIDIT II - PegIFN-alfa2a Plus Tenofovir in Chronic Delta Hepatitis Phase 2
Completed NCT06360484 - Prevalence and Clinical Characterization of Hepatitis D Virus (HDV) Infection Among Sudanese Patients With Hepatitis B Virus
Completed NCT02511431 - Treatment of Chronic Delta Hepatitis With Lonafarnib and Ritonavir Phase 2
Not yet recruiting NCT05451082 - Registry-based Study in Patients With Hepatitis D Virus (HDV) Infection in China
Recruiting NCT05903742 - Standardising Care for Hepatitis Delta in the Netherlands
Not yet recruiting NCT03362866 - Epidemiology of Hepatitis B, C and Delta in Reunion Island
Terminated NCT01316185 - Proof-of-concept Study Evaluating the Safety and Efficacy of EBP921 in Delta Hepatitis (HDV) Phase 1
Recruiting NCT05264272 - Disease Loads and Status of Treatment
Completed NCT05002907 - Epidemiology of Hepatitis B, C and D and HIV Along the Maroni River Bordering French Guiana and Suriname (MaHeVi)